1-2 of 2
William L. Carroll, MD, PhD
Close
Sort by
Journal Articles

Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031.

Kirk R. Schultz, MD, W. Paul Bowman, MD, William Slayton, MD/PhD, Alex Aledo, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, Michael J. Borowitz, MD/PhD, Stella M. Davies, MD/PhD, Michael Trigg, MD, Bernice Pasut, Dean Jorstad, Tammie Eslinger, Laura E. Burden, Chenguang Wang, PhD, Robert Rutledge, MD, Paul S. Gaynon, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Naomi Winick, MD, Stephen Hunger, MD/PhD, William L. Carroll, MD/PhD, Bruce Camitta, MD/PhD
Journal: Blood
Blood (2007) 110 (11): 4.
https://doi.org/10.1182/blood.V110.11.4.4
Published: 2007
Journal Articles

Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.

Kirk R. Schultz, MD, Alexander Aledo, MD, W. Paul Bowman, MD, William Slayton, MD, PhD, Harland Sather, PhD, Cheryl L. Willman, PhD, Julie M. Gastier-Foster, PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Michael J. Borowitz, PhD, Naomi Winick, MD, Stephen P. Hunger, MD, PhD, William L. Carroll, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 283.
https://doi.org/10.1182/blood.V108.11.283.283
Published: 2006